Primary sclerosing cholangitis: Refinement and validation of survival models

E. Rolland Dickson, Paul A. Murtaugh, Russell H. Wiesner, Patricia M. Grambsch, Thomas R. Fleming, Jurgen Ludwig, Nicholas F. LaRusso, Michael Malinchoc, Roger W. Chapman, Marshall M. Kaplan, Willis C. Maddrey, Roger Williams, Mark Farrant, Alice Langworthy

Research output: Contribution to journalArticle

224 Citations (Scopus)

Abstract

The natural history of primary sclerosing cholangitis was studied in 426 patients from five medical centers. The median follow-up time was 3.0 years (range, 0.01-16.6 years); 100 patients had died by the time of last follow-up. Survival analysis (Cox proportional-hazards regression) was used to identify the variables most useful in predicting survival of patients with primary sclerosing cholangitis. Serum bilirubin concentration, histological stage on liver biopsy, age, and the presence of splenomegaly were independent predictors of a high risk of dying. A mathematical model to predict survival of patients with primary sclerosing cholangitis (based on referral values of those predictors) was statistically validated using two methods. Confidence intervals for predicting patient-specific survival probabilities are also presented. This model to predict survival could be used to stratify participants in therapeutic trials, counsel patients and their families, decide on candidacy for and timing of liver transplantation, and provide mathematical controls for evaluating the efficacy of therapies for primary sclerosing cholangitis, including transplantation.

Original languageEnglish (US)
Pages (from-to)1893-1901
Number of pages9
JournalGastroenterology
Volume103
Issue number6
StatePublished - 1992

Fingerprint

Sclerosing Cholangitis
Survival
Splenomegaly
Survival Analysis
Bilirubin
Liver Transplantation
Theoretical Models
Referral and Consultation
Transplantation
Confidence Intervals
Biopsy
Liver
Therapeutics
Serum

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Dickson, E. R., Murtaugh, P. A., Wiesner, R. H., Grambsch, P. M., Fleming, T. R., Ludwig, J., ... Langworthy, A. (1992). Primary sclerosing cholangitis: Refinement and validation of survival models. Gastroenterology, 103(6), 1893-1901.

Primary sclerosing cholangitis : Refinement and validation of survival models. / Dickson, E. Rolland; Murtaugh, Paul A.; Wiesner, Russell H.; Grambsch, Patricia M.; Fleming, Thomas R.; Ludwig, Jurgen; LaRusso, Nicholas F.; Malinchoc, Michael; Chapman, Roger W.; Kaplan, Marshall M.; Maddrey, Willis C.; Williams, Roger; Farrant, Mark; Langworthy, Alice.

In: Gastroenterology, Vol. 103, No. 6, 1992, p. 1893-1901.

Research output: Contribution to journalArticle

Dickson, ER, Murtaugh, PA, Wiesner, RH, Grambsch, PM, Fleming, TR, Ludwig, J, LaRusso, NF, Malinchoc, M, Chapman, RW, Kaplan, MM, Maddrey, WC, Williams, R, Farrant, M & Langworthy, A 1992, 'Primary sclerosing cholangitis: Refinement and validation of survival models', Gastroenterology, vol. 103, no. 6, pp. 1893-1901.
Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J et al. Primary sclerosing cholangitis: Refinement and validation of survival models. Gastroenterology. 1992;103(6):1893-1901.
Dickson, E. Rolland ; Murtaugh, Paul A. ; Wiesner, Russell H. ; Grambsch, Patricia M. ; Fleming, Thomas R. ; Ludwig, Jurgen ; LaRusso, Nicholas F. ; Malinchoc, Michael ; Chapman, Roger W. ; Kaplan, Marshall M. ; Maddrey, Willis C. ; Williams, Roger ; Farrant, Mark ; Langworthy, Alice. / Primary sclerosing cholangitis : Refinement and validation of survival models. In: Gastroenterology. 1992 ; Vol. 103, No. 6. pp. 1893-1901.
@article{6b2af339c9d74993af34f87c8bbceb79,
title = "Primary sclerosing cholangitis: Refinement and validation of survival models",
abstract = "The natural history of primary sclerosing cholangitis was studied in 426 patients from five medical centers. The median follow-up time was 3.0 years (range, 0.01-16.6 years); 100 patients had died by the time of last follow-up. Survival analysis (Cox proportional-hazards regression) was used to identify the variables most useful in predicting survival of patients with primary sclerosing cholangitis. Serum bilirubin concentration, histological stage on liver biopsy, age, and the presence of splenomegaly were independent predictors of a high risk of dying. A mathematical model to predict survival of patients with primary sclerosing cholangitis (based on referral values of those predictors) was statistically validated using two methods. Confidence intervals for predicting patient-specific survival probabilities are also presented. This model to predict survival could be used to stratify participants in therapeutic trials, counsel patients and their families, decide on candidacy for and timing of liver transplantation, and provide mathematical controls for evaluating the efficacy of therapies for primary sclerosing cholangitis, including transplantation.",
author = "Dickson, {E. Rolland} and Murtaugh, {Paul A.} and Wiesner, {Russell H.} and Grambsch, {Patricia M.} and Fleming, {Thomas R.} and Jurgen Ludwig and LaRusso, {Nicholas F.} and Michael Malinchoc and Chapman, {Roger W.} and Kaplan, {Marshall M.} and Maddrey, {Willis C.} and Roger Williams and Mark Farrant and Alice Langworthy",
year = "1992",
language = "English (US)",
volume = "103",
pages = "1893--1901",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Primary sclerosing cholangitis

T2 - Refinement and validation of survival models

AU - Dickson, E. Rolland

AU - Murtaugh, Paul A.

AU - Wiesner, Russell H.

AU - Grambsch, Patricia M.

AU - Fleming, Thomas R.

AU - Ludwig, Jurgen

AU - LaRusso, Nicholas F.

AU - Malinchoc, Michael

AU - Chapman, Roger W.

AU - Kaplan, Marshall M.

AU - Maddrey, Willis C.

AU - Williams, Roger

AU - Farrant, Mark

AU - Langworthy, Alice

PY - 1992

Y1 - 1992

N2 - The natural history of primary sclerosing cholangitis was studied in 426 patients from five medical centers. The median follow-up time was 3.0 years (range, 0.01-16.6 years); 100 patients had died by the time of last follow-up. Survival analysis (Cox proportional-hazards regression) was used to identify the variables most useful in predicting survival of patients with primary sclerosing cholangitis. Serum bilirubin concentration, histological stage on liver biopsy, age, and the presence of splenomegaly were independent predictors of a high risk of dying. A mathematical model to predict survival of patients with primary sclerosing cholangitis (based on referral values of those predictors) was statistically validated using two methods. Confidence intervals for predicting patient-specific survival probabilities are also presented. This model to predict survival could be used to stratify participants in therapeutic trials, counsel patients and their families, decide on candidacy for and timing of liver transplantation, and provide mathematical controls for evaluating the efficacy of therapies for primary sclerosing cholangitis, including transplantation.

AB - The natural history of primary sclerosing cholangitis was studied in 426 patients from five medical centers. The median follow-up time was 3.0 years (range, 0.01-16.6 years); 100 patients had died by the time of last follow-up. Survival analysis (Cox proportional-hazards regression) was used to identify the variables most useful in predicting survival of patients with primary sclerosing cholangitis. Serum bilirubin concentration, histological stage on liver biopsy, age, and the presence of splenomegaly were independent predictors of a high risk of dying. A mathematical model to predict survival of patients with primary sclerosing cholangitis (based on referral values of those predictors) was statistically validated using two methods. Confidence intervals for predicting patient-specific survival probabilities are also presented. This model to predict survival could be used to stratify participants in therapeutic trials, counsel patients and their families, decide on candidacy for and timing of liver transplantation, and provide mathematical controls for evaluating the efficacy of therapies for primary sclerosing cholangitis, including transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0026458520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026458520&partnerID=8YFLogxK

M3 - Article

C2 - 1451982

AN - SCOPUS:0026458520

VL - 103

SP - 1893

EP - 1901

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 6

ER -